News | September 25, 2007

US Oncology Questions Ruling Restricting Anemia Management Protocols

September 26, 2007 — US Oncology expressed "deep concern" over a letter recently released by the Centers for Medicare and Medicaid Services (CMS).

According to a press release issued on its website, US Oncology believes that this new government policy outlined in the letter severely interferes with cancer doctors’ treatment protocols, creates a two-tiered system of cancer care in America, and potentially forces many cancer patients already undergoing chemotherapy treatment to undergo avoidable blood transfusions.

The letter, addressed to the American Society of Hematology, US Oncology and the American Society of Clinical Oncology, outlined limitations on coverage of erythropoietin stimulating agents for cancer patients.

ESAs are regarded as an integral drug as part of treatment protocols in cancer patients undergoing radiation and chemotherapy. ESAs, which are an injectable biologic, increase oxygen-carrying blood in patients who are anemia deficient due to chemotherapy treatments by naturally stimulating the body to produce more red blood cells.

The alternative to ESAs are blood transfusions, which are more cumbersome and carry various health risks, and could measurably reduce the nation's blood supply due to this policy, according to recent estimates.

According to US Oncology, under the new policy, Medicare beneficiaries risk dropping to hemoglobin levels oncologists regard as inappropriately low levels, and as a result, will risk being forced to undergo blood transfusions.

For more information: www.usoncology.com

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init